for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Athersys, Inc.

ATHX.OQ

Latest Trade

1.34USD

Change

-0.04(-2.90%)

Volume

80,028

Today's Range

1.34

 - 

1.37

52 Week Range

1.20

 - 

2.14

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.38
Open
1.36
Volume
80,028
3M AVG Volume
10.88
Today's High
1.37
Today's Low
1.34
52 Week High
2.14
52 Week Low
1.20
Shares Out (MIL)
152.68
Market Cap (MIL)
210.70
Forward P/E
-3.83
Dividend (Yield %)
--

Next Event

Athersys Inc at Dawson James Securities Small Cap Growth Conference

Latest Developments

More

Athersys Q2 Loss Per Share $0.06

Athersys Inc Enters Open Market Sale Agreement With Jefferies LLC To Offer And Sell Shares Up To $50.0 Million

Athersys Reports Q1 Loss Per Share $0.09

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Athersys, Inc.

Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Industry

Biotechnology & Drugs

Contact Info

3201 Carnegie Ave

+1.216.4319900

http://www.athersys.com/

Executive Leadership

Gil Van Bokkelen

Chairman of the Board, Chief Executive Officer

William B.J. Lehmann

President, Chief Operating Officer

John J. Harrington

Executive Vice President, Chief Scientific Officer, Director

Laura K. Campbell

Senior Vice President - Finance

Lee E. Babiss

Lead Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.180

2017

-0.290

2018

-0.180

2019(E)

-0.330
Price To Earnings (TTM)
--
Price To Sales (TTM)
22.08
Price To Book (MRQ)
6.30
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-90.30
Return on Equity (TTM)
-69.29

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up